Mundipharma today announced positive Phase III topline results from the global ReSPECT clinical trial evaluating REZZAYO® (rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in ...

Cancer cells can disarm the immune system not just by hiding from it, but by actively reprogramming nearby immune cells into a suppressed state. This previously unrecognized molecular interaction, ...

Researchers at Hannover Medical School have developed a benchtop bioreactor system that can generate up to 40 million human macrophages per week from induced pluripotent stem cells. The medium-scale ...

The study primary endpoint was met, showing non-inferiority vs. standard antimicrobial regimen in fungal free survival at Day 90 –– Study ...

Single agent duvelisib demonstrated clinically meaningful response rates, including a substantial proportion of complete responses, in a heavily pretreated PTCL population ...

UAB researchers have launched DiaClue, a free web-based tool that helps clinicians classify diabetes into five subtypes, ...

Becca Behler thought she had her life and career in front of her. It was early summer in 2020, and Becca had recently ...

The FDA has granted accelerated approval to Otarmeni™ (lunsotogene parvec-cwha), the first gene therapy for pediatric and adult patients with OTOF-related sensorineural hearing loss.

The EMA has recommended label expansions for Inaqovi, Opdivo, and Venclyxto, broadening treatment options in AML, Hodgkin lymphoma, and CLL.

“Our study highlights the growing potential of advanced biomarker science, combined with machine learning, to detect cancers ...